期刊论文详细信息
Journal of Clinical Medicine
Brain Metastases from Adult Sarcomas: A Retrospective Cohort Study from the Hellenic Group of Sarcomas and Rare Cancers (HGSRC)
Ioannis Boukovinas1  Stefania Kokkali2  Louiza Vini3  Anastasia Stergioula4  Nikolaos Vassos5  Anastasios Kyriazoglou6 
[1] Department of Medical Oncology, Bioclinic Hospital, 54622 Thessaloniki, Greece;Department of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece;Department of Radiation Oncology, Athens Medical Center, 15125 Marousi, Greece;Department of Radiation Oncology, “Iaso” Hospital, 15123 Marousi, Greece;Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, 68167 Mannheim, Germany;Medical Oncology Unit, Department of Clinical Therapeutics, General Hospital Alexandra, 11528 Athens, Greece;
关键词: brain metastases;    cerebral metastases;    soft tissue sarcoma;    bone sarcoma;   
DOI  :  10.3390/jcm10245978
来源: DOAJ
【 摘 要 】

Brain metastases are rare events in patients with sarcoma and the available information is relatively limited. We retrospectively reviewed medical records of patients with sarcoma who developed brain metastases between April 2010 and April 2020 in six centers. Thirty-four adult patients were included with a median age at brain metastases diagnosis of 55.5 years (range, 18–75). The primary sarcomas originated either from soft tissue (n = 27) or bone (n = 7) and the most common subtypes were leiomyosarcoma (n = 8), Ewing sarcoma/peripheral neuroectodermal tumor (PNET) (n = 7) and osteosarcoma (n = 3). Most primary tumors were of high grade and located mainly in the extremities (n = 18). The vast majority of patients at the time of brain metastasis diagnosis already had extracranial metastatic disease (n = 26). The median time from sarcoma diagnosis to cerebral metastasis diagnosis was 16 months (range, 1–136). Treatment modalities for brain metastatic disease included whole-brain radiation therapy (WBRT) (n = 22), chemotherapy (n = 17), exclusive palliative care (n = 5), surgery (n = 9), targeted therapy (n = 6) or stereotactic radiosurgery (n = 2). Most patients experienced a progression of brain metastases (n = 11). The median overall survival from brain metastasis diagnosis was 3 months (range, 0–80). OS was significantly influenced by time-to-brain metastases (p = 0.041), WBRT (p = 0.018), surgery (p = 0.002) and chemotherapy (p = 0.006). In a multivariate analysis, only the localization of the primary (p = 0.047) and WBRT (p = 0.038) were associated with survival with statistical significance. Patients with sarcoma brain metastases have a particularly poor prognosis and an appropriate therapeutic approach is yet to be defined.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次